Louise Frederika Kooij Sells 105,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 105,000 shares of the business’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $30.34, for a total value of $3,185,700.00. Following the sale, the chief accounting officer owned 24,353 shares in the company, valued at $738,870.02. The trade was a 81.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Louise Frederika Kooij also recently made the following trade(s):

• On Monday, June 22nd, Louise Frederika Kooij sold 40,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $30.20, for a total transaction of $1,208,000.00.
• On Tuesday, May 26th, Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.69, for a total value of $2,319,850.00.

NewAmsterdam Pharma Stock Down 0.3%

Shares of NASDAQ:NAMS opened at $27.91 on Thursday. NewAmsterdam Pharma Company N.V. has a 52-week low of $21.14 and a 52-week high of $42.21. The stock has a market cap of $3.26 billion, a price-to-earnings ratio of -15.59 and a beta of 0.08. The business has a 50-day moving average price of $32.45 and a 200-day moving average price of $32.73.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The business had revenue of $3.04 million during the quarter. As a group, equities analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current fiscal year.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NAMS. Duquesne Family Office LLC increased its stake in shares of NewAmsterdam Pharma by 131.2% during the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock worth $54,710,000 after purchasing an additional 1,091,525 shares in the last quarter. Castle Hook Partners LP purchased a new position in NewAmsterdam Pharma in the 4th quarter valued at about $38,062,000. Adage Capital Partners GP L.L.C. lifted its stake in NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after buying an additional 1,062,359 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in NewAmsterdam Pharma by 96.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,725,662 shares of the company’s stock worth $60,536,000 after buying an additional 845,110 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in NewAmsterdam Pharma by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after buying an additional 697,129 shares in the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

NAMS has been the subject of several recent research reports. BMO Capital Markets initiated coverage on shares of NewAmsterdam Pharma in a report on Monday, July 20th. They set an “outperform” rating and a $58.00 target price for the company. Royal Bank Of Canada lifted their price objective on shares of NewAmsterdam Pharma from $47.00 to $51.00 and gave the company an “outperform” rating in a report on Tuesday, June 30th. Jefferies Financial Group reissued a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Finally, Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, NewAmsterdam Pharma presently has an average rating of “Moderate Buy” and a consensus target price of $49.42.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.